| dc.description.abstract | Introduction: An outbreak of coronavirus disease 2019 or coronavirus disease 2019 (COVID-19) was first reported in December 2019 in Wuhan, Hubei Province, China. At that time, COVID-19 was known as a mysterious pneumonia caused by infection with the 2019 novel coronavirus (2019-nCoV), a newly discovered β-coronavirus. one of the most common laboratory test results in COVID-19 patients requiring hospitalization. Increased D-dimer and impaired hemostasis have also been reported to be associated with COVID-19 patients who do not survive. This research will involve as many as 36 people who suffer from COVID-19 and who are willing to take part in the research who are being hospitalized at H. Adam Malik General Hospital Medan. Methods: This study is a cross-sectional study which aims to determine the role of levels in assessing differences in D-dimer levels in mild, moderate and severe COVID-19 patients. This research was conducted at the Department of Clinical Pathology and at the Department of Pulmonology and Respiratory Medicine at USU FK/RSUP H. Adam Malik Medan using consecutive sampling methods starting from August 2021 - October 2021. Results: This study was attended by 36 confirmed Covid-19 people who were treated in the isolation room at H.Adam Malik General Hospital Medan. The age of the subjects showed an average of 50.92 years, with the most comorbid Hypertension and DM. The average D Dimer was 1324.28 ng/mL (SD = 2360.45 ng/mL) with the lowest value of 100 ng/mL and the highest value of 13420 ng /mL.
Conclusion: There was a significant difference in the D-dimer levels of moderate and severe COVID-19 patients treated at Adam Malik General Hospital, Medan. | en_US |
